A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder.

CONCLUSION: LAI-ris demonstrated similar effectiveness, safety and tolerability compared to oral AAP in this 6 month pilot trial. PMID: 17688463 [PubMed - indexed for MEDLINE]
Source: Acta Psychiatrica Scandinavica Supplementum - Category: Psychiatry Tags: Acta Psychiatr Scand Suppl Source Type: research